Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Journal of Clinical Oncology

Breast cancer patients in the US experienced a decline in cardiomyopathy-associated mortality from 1999 to 2017 (APC -3.1), followed by an increase from 2017 to 2023 (APC 3.3).

View Full Paper
Ask AI
Bookmark
Share

Population

9,568 adults aged ≥45 years in the United States who died with breast cancer and cardiomyopathy listed as…

Design

Cohort

Follow-up

1999-2023

Key result

Breast cancer patients in the US experienced a decline in cardiomyopathy-associated mortality from 1999 to 2017 (APC -3.1), followed by an increase from 2017 to 2023 (APC 3.3).

Authors

TMTanmayee MareeduEKElangovan KrishnanSASophia Ahmed

Discussion

Loading...

Member takes

Overview

Cardiomyopathy-associated mortality among breast cancer patients initially declined but has been increasing since 2017, particularly among older adults and specific demographic subgroups, highlighting the need for targeted cardio-oncology surveillance.

Key Points

  • This research aims to analyze national trends and disparities in cardiomyopathy-associated mortality among breast cancer survivors in the U.S. from 1999 to 2023.
  • Population-based analysis of CDC WONDER data from 1999-2023.
  • Calculated age-adjusted mortality rates and utilized joinpoint regression for trend analysis.
  • Stratified analyses by demographics, regions, and urbanization.
  • From 1999-2023, cardiomyopathy-associated deaths among breast cancer patients were 9,568.
  • Overall AAMR decreased from 4.1 to 2.4 (APC -3.1) until 2017, then rose to 2.72 (APC 3.3) post-2017.
  • Non-Hispanic Whites saw an increase in mortality rates, while non-Hispanic Blacks experienced a decline throughout the study period.

Study Design

Type

Observational (n=9,568)

Multicenter

Yes

Structured PICO

P
Population
9,568 adults aged ≥45 years in the United States who died with breast cancer and cardiomyopathy listed as contributing causes of death between 1999 and 2023.
O
Outcome
Age-adjusted mortality rates (AAMRs) per 1,000,000 population for cardiomyopathy-associated deathshard clinical

Cardiomyopathy-associated mortality among breast cancer patients initially declined but has been increasing since 2017, particularly among older adults and specific demographic subgroups, highlighting the need for targeted cardio-oncology surveillance.

Cite This Study

Mareedu et al. (2026) conducted an observational in Breast cancer and cardiomyopathy (n=9,568). Observation of mortality trends was evaluated on Age-adjusted mortality rates (AAMRs) per 1,000,000 population. Breast cancer patients in the US experienced a decline in cardiomyopathy-associated mortality from 1999 to 2017 (APC -3.1), followed by an increase from 2017 to 2023 (APC 3.3).

synapsesocial.com/papers/6a1a820e0307b78509433bf1https://doi.org/10.1200/jco.2026.44.16_suppl.e13141
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inequities in breast cancer mortality with contributing cardiometabolic disorders among U.S. women aged ≥45 years, 1999–2024.2026
  2. 2Shifting burden of cardiomyopathy deaths among United States cancer patients: A 25-year CDC WONDER analysis.2026
  3. 3Cardiomyopathy mortality among U.S. adults with breast cancer: A 25-year CDC WONDER study.2026
  4. 4Temporal Trends and Disparities in Hypertension‐Related Cardiomyopathy Mortality in the United States, 1999–20232026
  5. 5Mortality trends among U.S. adults with breast cancer and hypertensive diseases: A nationwide CDC WONDER analysis from 1999 to 2023.2026